Pfizer’s mRNA flu vaccine met each primary finishissues within the 18- to 64-year-old popul. a.tion in an onpassing Section III trial, the companew york announced on Tuesday morning. However, executives are not shooting for a 2024 release.
Whilst Pfizer initially pegged a possible 2024 release for its standon my own mRNA flu vaccine, that timing has been driven to “after 2024.” Its next-generation mRNA flu and Covid-19 combination vaccine is expected to release in 2025, CEO Albert Bourla stated in prepared remarks forward of the companew york’s third-quarter earnings name.
Release this newsletter straight away through turning into a loose subscriber.
You’ll get get entry to to loose articles every month, plus you’ll customise what newsletters get delivered on your inbox every week, together with breaking information.